Ryman rights trading ends on a sour note

Ryman rights trading ends on a sour note
Salt Funds' Matt Goodson said time will tell whether Ryman shares are cheap. (Image: Salt Funds)
Jenny Ruth
Ryman Healthcare’s $902 million rights issue is drawing to a dismal close, with the price of the rights falling as low as 7.5 cents on Tuesday, the last day of trading.Two weeks ago, in the institutional book-build auction process, institutional investors were prepared to pay an effective $1 for the rights.You could say that was a little disappointing because the theoretical value of the rights price was $1.03 – institutions paid $6 for the shares issued at $5, so the additional price paid reflected the value they put on the rights....

More Finance

Andrew Barclay to leave Goldman Sachs NZ
Finance

Andrew Barclay to leave Goldman Sachs NZ

Andrew Barclay has been one of NZ’s most respected deal-makers.

Pattrick Smellie 20 May 2025
How Sharesies is providing ‘patient’ capital for listeds
Finance

How Sharesies is providing ‘patient’ capital for listeds

The online platform is being tapped for bookbuilds and dividend reinvestment plans.

Fonterra boss wins big at INFINZ awards
Finance

Fonterra boss wins big at INFINZ awards

Michele Embling became a fellow of the institute. 

Staff reporters 13 May 2025
No longer 'boutique' Generate is executing, CEO says
Finance

No longer 'boutique' Generate is executing, CEO says

The fund manager is now the seventh-largest KiwiSaver provider.

Gregor Thompson 09 May 2025